{"success":true,"data":{"pressRelease":{"id":"157240","rtpr_id":"nGNX1V8WmY-20260930","ticker":"LGVN","exchange":"NASDAQ","all_tickers":["LGVN"],"title":"Longeveron to Participate in Three Longevity/Aging Investment Conferences","author":"Globe Newswire","published_at":"2026-09-30T20:05:00.310Z","article_body":"MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc.\n(https://www.globenewswire.com/Tracker?data=QXYdiVTuezxILtvurRVbYDAkLzI71hq2-D9XFd-n7CS8SozTbFQSJ5S37Un2TP9Gfzb0Eb7_L2vGpY_GJlVtpmRFMZz0rdIF3LGhPWqBoC4=)\n(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company\ndeveloping cellular therapies for life-threatening and chronic aging-related\nconditions, today announced that it will participate in three upcoming\nLongevity/Aging investment conferences.\n\n13th Aging Research and Drug Discovery Meeting\n(https://www.globenewswire.com/Tracker?data=IxZO0aAAChSk6Kcv0ju98xxf2fadEas6cC-ATbOtC9QexSUqqHzrn5ZuAP0bNgbc4hfbS7rB7JDXY6N2aOpm0NJyRq0M3q1401pO0gtkCD96VhjdcYnO4QpQfwUDOzsGWHtCc1EwumwAfOTyST_c0g==)\n(ARDD) to be held October 1-3, 2026 in Boston\n\nAbundance Longevity Trip\n(https://www.globenewswire.com/Tracker?data=MwwhO1C0U9pLr12diZEjQe1FI9ishbpBfEpTTo9KTNLac9TOvGcDcaB5V-Wy6TjG6o9gHizUl00mlFKstjmxJS6Qbi64mgR1lPW9HQnFHPaNXTKLNecMVBDr6ZtGYbl3)\nto be held October 7-11, 2026 (virtual participation)\n\nLongevity Partnering Forum\n(https://www.globenewswire.com/Tracker?data=QXYdiVTuezxILtvurRVbYHw8r-pxnrusyVrsFGTGz1-sqhlaKP1qsLVKpxkoClHYofRs6ABeNlQlIFTn8YAranJB6YLrr1tnq-PKnhXnraJX37GTkZnR7ZW9HsGtAbPN)\nto be held October 19-20, 2026 in South San Francisco\n\nLongevity and Aging-Related Frailty\nThe Company intends to pursue funding sources and other potential revenue\nopportunities to advance laromestrocel in longevity and Aging-related Frailty.\nResults from a Phase 2b clinical trial demonstrated that intravenous\nlaromestrocel improved the physical condition of patients with age-related\nclinical frailty after nine months, compared to placebo. These results were\npublished in Cell Stem Cell\n(https://www.globenewswire.com/Tracker?data=01YQ9fKPJVR7S5ZxTvJRTdj6N6JfTdoflNmYp0Q_XCYgGTEB4ly_tlyNr94tzAFGMqiMzZFrvqLehDcZK2ZnBL8hYfZthi8Htmk6h19nEfR-ro0Zbg87q-w-MVhJEuhX)\nin February 2026. Further, based on these clinical trial results, Longeveron\nannounced in August 2026 that it was selected from over 600 worldwide\napplicants to advance to the final phase of the XPRIZE Healthspan\n(https://www.globenewswire.com/Tracker?data=Flo7WWQ84-5ZvxjiLMalEBDfS9cZ8WtsI2EGbTFm_i2zQ3GJmodKalp-Ivx3_16Fm1BKYFcfbr3qAnD7EPgE_ssHLaXNfiSMfEtKbXc0FMTfU_SroPDotAIBsa0yeyYb)\ncompetition as a Milestone 2 Awardee team. Longeveron received the $1,000,000\nMilestone 2 Award to be used towards the future competition clinical trial in\naccordance with the XPRIZE competition rules, with the opportunity to compete\nfor the XPRIZE Grand Prize of up to $81 million.\n\nNew Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published\non medRxiv\nThe Company has recently published a new manuscript as a pre-print in medRxiv,\ndetailing post-hoc exploratory analysis from the Company’s Phase 2a\nrandomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated\nlaromestrocel treatment may reduce neuroinflammation in the brain—a core\ndriver of AD pathogenesis, using free water MRI imaging.\n\nThis is a preprint and has not yet completed peer review. Laromestrocel is an\ninvestigational product and has not been approved by the FDA or any other\nregulatory agency.\n\nRead the full preprint:\nhttps://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1\n\nKey findings:\n* Laromestrocel inhibited the progression of neuroinflammation, with the\nstrongest effects in regions at the core of Alzheimer's pathology, including\nthe left hippocampus (p<0.001 in both the 25M and 100M cell dose groups), as\nwell as the temporal and parietal cortex.\n* Reduced neuroinflammation correlated with less brain atrophy and with\nimproved clinical scores, particularly cognition as measured by MoCA.\n* Treated participants showed lower plasma neurogranin, consistent with\nreduced synaptic loss.\n* Blood biomarker analyses point to a convergent, multimodal mechanism of\naction involving peripheral immune engagement.\nTogether, these results support the hypothesis that laromestrocel's potential\nanti-inflammatory effects may help protect brain tissue and function in\nAlzheimer's disease. If confirmed, durable anti-inflammatory effects may also\nbe useful in combatting chronic inflammation in aging, or “inflammaging”.\n\nThese new results follow publication of main CLEAR MIND trial results in\nNature Medicine in 2025. https://www.nature.com/articles/s41591-025-03559-0\n\nAbout laromestrocel (Lomecel-B(®))\nLaromestrocel is a living cell product made from specialized cells isolated\nfrom the bone marrow of young, healthy adult donors. These specialized cells,\nknown as mesenchymal stem cells (MSCs), are essential to the human endogenous\nbiological repair mechanism. MSCs have the potential to perform a number of\ncomplex functions in the body and possibly support tissue repair and\nregenerative signaling pathways. They also may respond to sites of injury or\ndisease and may secrete bioactive factors that are immunomodulatory and\nregenerative. We believe laromestrocel MSCs may have multiple potential\nmechanisms of action that may lead to anti-inflammatory, pro-vascular\nregenerative responses, and therefore may have broad application for a range\nof rare and aging related diseases.\n\nAbout Longeveron Inc.\nLongeveron is a clinical stage biotechnology company developing regenerative\nmedicines to address unmet medical needs. The Company’s lead investigational\nproduct is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell\n(MSC) therapy product isolated from the bone marrow of young, healthy adult\ndonors. We believe laromestrocel has multiple potential mechanisms of action\nencompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue\nrepair and healing effects with broad potential applications across a spectrum\nof disease areas. Longeveron is pursuing four pipeline indications:\nhypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric\nDilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel\ndevelopment programs have received five distinct and important FDA\ndesignations: for the HLHS program - Orphan Drug designation, Fast Track\ndesignation, and Rare Pediatric Disease designation; and, for the AD program -\nRegenerative Medicine Advanced Therapy (RMAT) designation and Fast Track\ndesignation. For more information, visit www.longeveron.com or follow\nLongeveron on LinkedIn\n(https://www.globenewswire.com/Tracker?data=UdCnScWRVLIlSVBUz4CPZTpi018kdE24tLn8Sxr-nh5eJaMLFHKLjAGTTzHpCYkw0PRL-4sxQZOUWig8a_0ecBYUqiUBYldhSZjY-ypVTsxJpBypzCDDFoBtXqA67BHQ),\nX\n(https://www.globenewswire.com/Tracker?data=KclECsONsh7Q9tspU9_Je4oK0iIr5bfIgwpPdumbCWvXETfmHoGSTOdx9VvhlTK53ris4tX5WMFeZdHFMSeJvw==),\nand Instagram\n(https://www.globenewswire.com/Tracker?data=Tm8OZLw3VOEP42a2O-z3q0E-5_vaOQeXKIUiXGBZtMCVjIsKcBvFH-tokwE4WCOlQlQmlM-bzKlU8IBdI0Ugw2RNqgRYPshEoPRldao_9vY=).\n\nForward-Looking Statements\nCertain statements in this press release that are not historical facts are\nforward-looking statements made pursuant to the safe harbor provisions of the\nPrivate Securities Litigation Reform Act of 1995, which reflect management’s\ncurrent expectations, assumptions, and estimates of future operations,\nperformance and economic conditions, and involve known and unknown risks,\nuncertainties, and other important factors that could cause actual results,\nperformance, or achievements to differ materially from those anticipated,\nexpressed, or implied by the statements made herein. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate, including our ability to pursue funding sources\nand potential revenue opportunities to advance laromestrocel in longevity and\nAging-related frailty; our expectations regarding the review and exploration\nof all options and their potential impact on shareholder value; our ability to\nengage an investment bank or other strategic advisor; the continued listing of\nour Class A common stock on Nasdaq; our expectations regarding the future of\nthe Company's operations, including our clinical, development and\ncommercialization activities; our plans to implement cash conservation\nmeasures to reduce operating expenses; and other statements regarding future\nevents. Forward-looking statements are generally identifiable by the use of\nforward-looking terminology such as “anticipate,” “believe,”\n“contemplate,” “continue,” “could,” “estimate,” “expects,”\n“intend,” “looks to,” “may,” “on condition,” “plan,”\n“potential,” “predict,” “preliminary,” “project,” “see,”\n“should,” “target,” “will,” “would,” or the negative thereof\nor comparable terminology, although not all forward-looking statements contain\nthese words, or by discussion of strategy or goals or other future events,\ncircumstances, or effects. Additional factors that could cause actual results\nto differ materially from those expressed or implied in any forward-looking\nstatements in this release include, but are not limited to, the risk that the\nexploration of strategic options may not result in any definitive transaction\nor enhance shareholder value or may create uncertainty that may adversely\naffect our business, financial condition, results of operations, or\nshareholder and investor perception; the ability of our clinical trials to\ndemonstrate safety and efficacy of our investigational product candidates, and\nother positive results; our ability to successfully transition toward a more\ncapital-efficient, asset-light operating model; our ability to secure one or\nmore strategic licensing partnerships for laromestrocel in our development\nprograms; our ability to reach alignment with the FDA and other regulatory\nauthorities on a potential path toward regulatory approval; the availability\nof evidence from our ongoing and future preclinical studies and clinical\ntrials sufficient to support the Company filing a BLA for the investigational\nproduct candidate for one or more indications; the timing and focus of our\nongoing and future preclinical studies and clinical trials, and the reporting\nof data from those studies and trials; market and other conditions, our cash\nposition and need to raise additional capital, the difficulties we may face in\nobtaining access to capital, and the dilutive impact it may have on our\ninvestors; our financial performance, and ability to continue as a going\nconcern; the period over which we estimate our existing cash and cash\nequivalents will be sufficient to fund our future operating expenses and\ncapital expenditure requirements; the size of the market opportunity for\ncertain of our investigational product candidates, including our estimates of\nthe number of patients who suffer from the diseases we are targeting; our\nability to scale production and commercialize the investigational product\ncandidate for certain indications; the success of competing therapies that are\nor may become available; the beneficial characteristics, safety, efficacy and\ntherapeutic effects of our investigational product candidates; our ability to\nobtain and maintain regulatory approval of our investigational product\ncandidates in the U.S. and other jurisdictions; our plans relating to the\nfurther development of our investigational product candidates, including\nadditional disease states or indications we may pursue; our plans and ability\nto obtain or protect intellectual property rights, including extensions of\nexisting patent terms where available and our ability to avoid infringing the\nintellectual property rights of others; the need to hire additional personnel\nand our ability to attract and retain such personnel; and our estimates\nregarding expenses, future revenue, capital requirements and needs for\nadditional financing.\n\nFurther information relating to factors that may impact the Company’s\nresults and forward-looking statements are disclosed in the Company’s\nfilings with the Securities and Exchange Commission, including Longeveron’s\nAnnual Report on Form 10-K for the year ended December 31, 2025, filed with\nthe Securities and Exchange Commission on March 17, 2026, its Quarterly\nReports on Form 10-Q, and its Current Reports on Form 8-K. The Company\noperates in a highly competitive and rapidly changing environment; therefore,\nnew factors may arise, and it is not possible for the Company’s management\nto predict all such factors that may arise nor assess the impact of such\nfactors or the extent to which any individual factor or combination thereof,\nmay cause results to differ materially from those contained in any\nforward-looking statements. The forward-looking statements contained in this\npress release are made as of the date of this press release based on\ninformation available as of the date of this press release, are inherently\nuncertain, and the Company disclaims any intention or obligation, other than\nimposed by law, to update or revise any forward-looking statements, whether as\na result of new information, future events, or otherwise.\n\nInvestor and Media Contact:\nDerek Cole \nInvestor Relations Advisory Solutions \nderek.cole@iradvisory.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/69d2cfdc-39bf-4128-a6c3-1cabc29e603d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1V8WmY-20260930","title":"Longeveron to Participate in Three Longevity/Aging Investment Conferences","author":"Globe Newswire","ticker":"LGVN","created":"2026-09-30T20:05:00.310Z","tickers":["LGVN"],"exchange":"NASDAQ","article_body":"MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc.\n(https://www.globenewswire.com/Tracker?data=QXYdiVTuezxILtvurRVbYDAkLzI71hq2-D9XFd-n7CS8SozTbFQSJ5S37Un2TP9Gfzb0Eb7_L2vGpY_GJlVtpmRFMZz0rdIF3LGhPWqBoC4=)\n(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company\ndeveloping cellular therapies for life-threatening and chronic aging-related\nconditions, today announced that it will participate in three upcoming\nLongevity/Aging investment conferences.\n\n13th Aging Research and Drug Discovery Meeting\n(https://www.globenewswire.com/Tracker?data=IxZO0aAAChSk6Kcv0ju98xxf2fadEas6cC-ATbOtC9QexSUqqHzrn5ZuAP0bNgbc4hfbS7rB7JDXY6N2aOpm0NJyRq0M3q1401pO0gtkCD96VhjdcYnO4QpQfwUDOzsGWHtCc1EwumwAfOTyST_c0g==)\n(ARDD) to be held October 1-3, 2026 in Boston\n\nAbundance Longevity Trip\n(https://www.globenewswire.com/Tracker?data=MwwhO1C0U9pLr12diZEjQe1FI9ishbpBfEpTTo9KTNLac9TOvGcDcaB5V-Wy6TjG6o9gHizUl00mlFKstjmxJS6Qbi64mgR1lPW9HQnFHPaNXTKLNecMVBDr6ZtGYbl3)\nto be held October 7-11, 2026 (virtual participation)\n\nLongevity Partnering Forum\n(https://www.globenewswire.com/Tracker?data=QXYdiVTuezxILtvurRVbYHw8r-pxnrusyVrsFGTGz1-sqhlaKP1qsLVKpxkoClHYofRs6ABeNlQlIFTn8YAranJB6YLrr1tnq-PKnhXnraJX37GTkZnR7ZW9HsGtAbPN)\nto be held October 19-20, 2026 in South San Francisco\n\nLongevity and Aging-Related Frailty\nThe Company intends to pursue funding sources and other potential revenue\nopportunities to advance laromestrocel in longevity and Aging-related Frailty.\nResults from a Phase 2b clinical trial demonstrated that intravenous\nlaromestrocel improved the physical condition of patients with age-related\nclinical frailty after nine months, compared to placebo. These results were\npublished in Cell Stem Cell\n(https://www.globenewswire.com/Tracker?data=01YQ9fKPJVR7S5ZxTvJRTdj6N6JfTdoflNmYp0Q_XCYgGTEB4ly_tlyNr94tzAFGMqiMzZFrvqLehDcZK2ZnBL8hYfZthi8Htmk6h19nEfR-ro0Zbg87q-w-MVhJEuhX)\nin February 2026. Further, based on these clinical trial results, Longeveron\nannounced in August 2026 that it was selected from over 600 worldwide\napplicants to advance to the final phase of the XPRIZE Healthspan\n(https://www.globenewswire.com/Tracker?data=Flo7WWQ84-5ZvxjiLMalEBDfS9cZ8WtsI2EGbTFm_i2zQ3GJmodKalp-Ivx3_16Fm1BKYFcfbr3qAnD7EPgE_ssHLaXNfiSMfEtKbXc0FMTfU_SroPDotAIBsa0yeyYb)\ncompetition as a Milestone 2 Awardee team. Longeveron received the $1,000,000\nMilestone 2 Award to be used towards the future competition clinical trial in\naccordance with the XPRIZE competition rules, with the opportunity to compete\nfor the XPRIZE Grand Prize of up to $81 million.\n\nNew Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published\non medRxiv\nThe Company has recently published a new manuscript as a pre-print in medRxiv,\ndetailing post-hoc exploratory analysis from the Company’s Phase 2a\nrandomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated\nlaromestrocel treatment may reduce neuroinflammation in the brain—a core\ndriver of AD pathogenesis, using free water MRI imaging.\n\nThis is a preprint and has not yet completed peer review. Laromestrocel is an\ninvestigational product and has not been approved by the FDA or any other\nregulatory agency.\n\nRead the full preprint:\nhttps://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1\n\nKey findings:\n* Laromestrocel inhibited the progression of neuroinflammation, with the\nstrongest effects in regions at the core of Alzheimer's pathology, including\nthe left hippocampus (p<0.001 in both the 25M and 100M cell dose groups), as\nwell as the temporal and parietal cortex.\n* Reduced neuroinflammation correlated with less brain atrophy and with\nimproved clinical scores, particularly cognition as measured by MoCA.\n* Treated participants showed lower plasma neurogranin, consistent with\nreduced synaptic loss.\n* Blood biomarker analyses point to a convergent, multimodal mechanism of\naction involving peripheral immune engagement.\nTogether, these results support the hypothesis that laromestrocel's potential\nanti-inflammatory effects may help protect brain tissue and function in\nAlzheimer's disease. If confirmed, durable anti-inflammatory effects may also\nbe useful in combatting chronic inflammation in aging, or “inflammaging”.\n\nThese new results follow publication of main CLEAR MIND trial results in\nNature Medicine in 2025. https://www.nature.com/articles/s41591-025-03559-0\n\nAbout laromestrocel (Lomecel-B(®))\nLaromestrocel is a living cell product made from specialized cells isolated\nfrom the bone marrow of young, healthy adult donors. These specialized cells,\nknown as mesenchymal stem cells (MSCs), are essential to the human endogenous\nbiological repair mechanism. MSCs have the potential to perform a number of\ncomplex functions in the body and possibly support tissue repair and\nregenerative signaling pathways. They also may respond to sites of injury or\ndisease and may secrete bioactive factors that are immunomodulatory and\nregenerative. We believe laromestrocel MSCs may have multiple potential\nmechanisms of action that may lead to anti-inflammatory, pro-vascular\nregenerative responses, and therefore may have broad application for a range\nof rare and aging related diseases.\n\nAbout Longeveron Inc.\nLongeveron is a clinical stage biotechnology company developing regenerative\nmedicines to address unmet medical needs. The Company’s lead investigational\nproduct is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell\n(MSC) therapy product isolated from the bone marrow of young, healthy adult\ndonors. We believe laromestrocel has multiple potential mechanisms of action\nencompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue\nrepair and healing effects with broad potential applications across a spectrum\nof disease areas. Longeveron is pursuing four pipeline indications:\nhypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric\nDilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel\ndevelopment programs have received five distinct and important FDA\ndesignations: for the HLHS program - Orphan Drug designation, Fast Track\ndesignation, and Rare Pediatric Disease designation; and, for the AD program -\nRegenerative Medicine Advanced Therapy (RMAT) designation and Fast Track\ndesignation. For more information, visit www.longeveron.com or follow\nLongeveron on LinkedIn\n(https://www.globenewswire.com/Tracker?data=UdCnScWRVLIlSVBUz4CPZTpi018kdE24tLn8Sxr-nh5eJaMLFHKLjAGTTzHpCYkw0PRL-4sxQZOUWig8a_0ecBYUqiUBYldhSZjY-ypVTsxJpBypzCDDFoBtXqA67BHQ),\nX\n(https://www.globenewswire.com/Tracker?data=KclECsONsh7Q9tspU9_Je4oK0iIr5bfIgwpPdumbCWvXETfmHoGSTOdx9VvhlTK53ris4tX5WMFeZdHFMSeJvw==),\nand Instagram\n(https://www.globenewswire.com/Tracker?data=Tm8OZLw3VOEP42a2O-z3q0E-5_vaOQeXKIUiXGBZtMCVjIsKcBvFH-tokwE4WCOlQlQmlM-bzKlU8IBdI0Ugw2RNqgRYPshEoPRldao_9vY=).\n\nForward-Looking Statements\nCertain statements in this press release that are not historical facts are\nforward-looking statements made pursuant to the safe harbor provisions of the\nPrivate Securities Litigation Reform Act of 1995, which reflect management’s\ncurrent expectations, assumptions, and estimates of future operations,\nperformance and economic conditions, and involve known and unknown risks,\nuncertainties, and other important factors that could cause actual results,\nperformance, or achievements to differ materially from those anticipated,\nexpressed, or implied by the statements made herein. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate, including our ability to pursue funding sources\nand potential revenue opportunities to advance laromestrocel in longevity and\nAging-related frailty; our expectations regarding the review and exploration\nof all options and their potential impact on shareholder value; our ability to\nengage an investment bank or other strategic advisor; the continued listing of\nour Class A common stock on Nasdaq; our expectations regarding the future of\nthe Company's operations, including our clinical, development and\ncommercialization activities; our plans to implement cash conservation\nmeasures to reduce operating expenses; and other statements regarding future\nevents. Forward-looking statements are generally identifiable by the use of\nforward-looking terminology such as “anticipate,” “believe,”\n“contemplate,” “continue,” “could,” “estimate,” “expects,”\n“intend,” “looks to,” “may,” “on condition,” “plan,”\n“potential,” “predict,” “preliminary,” “project,” “see,”\n“should,” “target,” “will,” “would,” or the negative thereof\nor comparable terminology, although not all forward-looking statements contain\nthese words, or by discussion of strategy or goals or other future events,\ncircumstances, or effects. Additional factors that could cause actual results\nto differ materially from those expressed or implied in any forward-looking\nstatements in this release include, but are not limited to, the risk that the\nexploration of strategic options may not result in any definitive transaction\nor enhance shareholder value or may create uncertainty that may adversely\naffect our business, financial condition, results of operations, or\nshareholder and investor perception; the ability of our clinical trials to\ndemonstrate safety and efficacy of our investigational product candidates, and\nother positive results; our ability to successfully transition toward a more\ncapital-efficient, asset-light operating model; our ability to secure one or\nmore strategic licensing partnerships for laromestrocel in our development\nprograms; our ability to reach alignment with the FDA and other regulatory\nauthorities on a potential path toward regulatory approval; the availability\nof evidence from our ongoing and future preclinical studies and clinical\ntrials sufficient to support the Company filing a BLA for the investigational\nproduct candidate for one or more indications; the timing and focus of our\nongoing and future preclinical studies and clinical trials, and the reporting\nof data from those studies and trials; market and other conditions, our cash\nposition and need to raise additional capital, the difficulties we may face in\nobtaining access to capital, and the dilutive impact it may have on our\ninvestors; our financial performance, and ability to continue as a going\nconcern; the period over which we estimate our existing cash and cash\nequivalents will be sufficient to fund our future operating expenses and\ncapital expenditure requirements; the size of the market opportunity for\ncertain of our investigational product candidates, including our estimates of\nthe number of patients who suffer from the diseases we are targeting; our\nability to scale production and commercialize the investigational product\ncandidate for certain indications; the success of competing therapies that are\nor may become available; the beneficial characteristics, safety, efficacy and\ntherapeutic effects of our investigational product candidates; our ability to\nobtain and maintain regulatory approval of our investigational product\ncandidates in the U.S. and other jurisdictions; our plans relating to the\nfurther development of our investigational product candidates, including\nadditional disease states or indications we may pursue; our plans and ability\nto obtain or protect intellectual property rights, including extensions of\nexisting patent terms where available and our ability to avoid infringing the\nintellectual property rights of others; the need to hire additional personnel\nand our ability to attract and retain such personnel; and our estimates\nregarding expenses, future revenue, capital requirements and needs for\nadditional financing.\n\nFurther information relating to factors that may impact the Company’s\nresults and forward-looking statements are disclosed in the Company’s\nfilings with the Securities and Exchange Commission, including Longeveron’s\nAnnual Report on Form 10-K for the year ended December 31, 2025, filed with\nthe Securities and Exchange Commission on March 17, 2026, its Quarterly\nReports on Form 10-Q, and its Current Reports on Form 8-K. The Company\noperates in a highly competitive and rapidly changing environment; therefore,\nnew factors may arise, and it is not possible for the Company’s management\nto predict all such factors that may arise nor assess the impact of such\nfactors or the extent to which any individual factor or combination thereof,\nmay cause results to differ materially from those contained in any\nforward-looking statements. The forward-looking statements contained in this\npress release are made as of the date of this press release based on\ninformation available as of the date of this press release, are inherently\nuncertain, and the Company disclaims any intention or obligation, other than\nimposed by law, to update or revise any forward-looking statements, whether as\na result of new information, future events, or otherwise.\n\nInvestor and Media Contact:\nDerek Cole \nInvestor Relations Advisory Solutions \nderek.cole@iradvisory.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/69d2cfdc-39bf-4128-a6c3-1cabc29e603d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T20:05:00.442686157Z","server_sent_at_ms":1790798700442},"received_at":"2026-09-30T20:05:00.504Z","source_url":null},"analysis":{"id":"145911","press_release_id":"157240","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Alzheimer's analysis is an unreviewed preprint with post-hoc exploratory design","Forward-looking statements reference going-concern, cash conservation, and continued Nasdaq listing risks"],"eventType":"other","narrative":"Longeveron will participate in three longevity/aging investment conferences in October 2026: the ARDD meeting in Boston, the Abundance Longevity Trip (virtual), and the Longevity Partnering Forum in South San Francisco.\n\nThe release recaps that laromestrocel Phase 2b frailty data was published in Cell Stem Cell and that the company won a $1 million XPRIZE Healthspan Milestone 2 Award, with a shot at a grand prize of up to $81 million.\n\nIt also highlights a new medRxiv preprint of post-hoc Phase 2a CLEAR MIND (n=49) analysis suggesting laromestrocel may reduce neuroinflammation in Alzheimer's disease; the data is not peer-reviewed and the product remains investigational.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-participation notice; suppress or file under pipeline awareness."},"keyFigures":{"customDimensions":{"clear_mind_trial_n":49,"xprize_milestone_award_usd":1000000,"xprize_grand_prize_up_to_usd":81000000}},"namedEntities":{"people":[{"name":"Derek Cole","role":"Investor and Media Contact"}],"products":["laromestrocel (Lomecel-B)"],"companies":[{"name":"Longeveron Inc.","ticker":"LGVN","relationship":"filer"},{"name":"XPRIZE Healthspan","relationship":"competition organizer"}],"dollarAmounts":[{"amount":"$1,000,000","context":"XPRIZE Healthspan Milestone 2 Award"},{"amount":"$81 million","context":"XPRIZE Grand Prize, up to"}]},"materialImpact":{"score":1,"reasoning":"Announcement of participation in three investor conferences — routine corporate communications with no new data, financing, or regulatory event. The recycled pipeline context adds no new material facts."},"tickerRelevance":{"others":[],"primary":"LGVN"},"globalImportance":8,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":["operations_update"],"sentiment":"neutral","material_impact_score":1,"narrative":"Longeveron will participate in three longevity/aging investment conferences in October 2026: the ARDD meeting in Boston, the Abundance Longevity Trip (virtual), and the Longevity Partnering Forum in South San Francisco.\n\nThe release recaps that laromestrocel Phase 2b frailty data was published in Cell Stem Cell and that the company won a $1 million XPRIZE Healthspan Milestone 2 Award, with a shot at a grand prize of up to $81 million.\n\nIt also highlights a new medRxiv preprint of post-hoc Phase 2a CLEAR MIND (n=49) analysis suggesting laromestrocel may reduce neuroinflammation in Alzheimer's disease; the data is not peer-reviewed and the product remains investigational.","key_figures":{"customDimensions":{"clear_mind_trial_n":49,"xprize_milestone_award_usd":1000000,"xprize_grand_prize_up_to_usd":81000000}},"named_entities":{"people":[{"name":"Derek Cole","role":"Investor and Media Contact"}],"products":["laromestrocel (Lomecel-B)"],"companies":[{"name":"Longeveron Inc.","ticker":"LGVN","relationship":"filer"},{"name":"XPRIZE Healthspan","relationship":"competition organizer"}],"dollarAmounts":[{"amount":"$1,000,000","context":"XPRIZE Healthspan Milestone 2 Award"},{"amount":"$81 million","context":"XPRIZE Grand Prize, up to"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:05:05.666Z","global_importance":8,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true,"newInformation":false}},"durationMs":5125,"modelName":"glm-5.3-flashx"}}